Result of the Open Offer

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the results of the open offer to shareholders (the "Open Offer"), the commencement of which was announced by the Company on 30 November 2023 (the "Launch Announcement").

The Open Offer closed for acceptances at 11.00 a.m. on 18 December 2023. The Company is pleased to announce that it has received valid applications under the Open Offer (including under the Excess Application Facility) in respect of 11,136,877 Open Offer Shares (the "New Open Offer Shares") at 11 pence per New Open Offer Share from Qualifying Shareholders raising gross proceeds from the Open Offer of £1.2 million.

The Open Offer is conditional upon Second Admission occurring. Application has been made to the London Stock Exchange for the New Open Offer Shares to be admitted to trading on AIM. It is expected that Second Admission will become effective and dealings will commence in the New Open Offer Shares at 8.00 a.m. on 20 December 2023.

This announcement should be read in conjunction with the full text of the circular published on 4 December 2023 (the "Circular"). The Circular is also available on the Company's website at www.Scancell.co.uk.

Total Voting Rights

Following Second Admission, the Company's enlarged issued ordinary share capital will be 927,819,977. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Confirmation of Gross Proceeds Raised

The Company has raised gross proceeds of approximately £11.9 million in aggregate (before expenses) through the Capital Raise (as first announced by the Company in the Launch Announcement). This is comprised of (i) gross proceeds of approximately £10.7 million in aggregate through the Placing and the Subscription with significant participation from both existing and new healthcare specialist investors and (ii) gross proceeds of approximately £1.2 million through the Open Offer reflecting renewed support from existing shareholders.

For further information please contact: Scancell Holdings plc Dr Jean-Michel Cosséry, Non-Executive Chairman Professor Lindy Durrant, CEO +44 (0) 20 3727 1000 +44 (0) 20 7886 2500 Stifel Nicolaus Europe Limited (Sole Financial Adviser, Joint Bookrunner, Nominated Adviser and Joint Broker) Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking) Nick Harland/Nick Adams (Corporate Broking) +44 (0) 20 7710 7600 WG Partners LLP (Joint Bookrunner) David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby +44 (0) 20 3705 9330 Panmure Gordon (UK) Limited (Joint Broker) Freddy Crossley/Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) +44 (0) 20 7886 2500 ICR Consilium Mary-Jane Elliot/Matthew Neal/ Chris Welsh +44 (0) 20 3709 5700 Scancell@consilium-comms.com

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM